Somapacitan LA is under clinical development by Novo Nordisk and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Somapacitan LA’s likelihood of approval (LoA) and phase transition for Born Small For Gestational Age (SGA) took place on 17 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 17 Nov 2022 increased Somapacitan LA’s LoA and PTSR for Noonan Syndrome.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Somapacitan LA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Somapacitan LA overview

Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

Somapacitan (NNC0195-0092) is under development for the treatment of growth hormone deficiency, born small for gestational age,Turner Syndrome, Noonan Syndrome, and idiopathic short stature. The drug candidate is administered subcutaneously as a solution. It acts by targeting somatotropin receptor. It is a long-acting albumin-binding growth hormone derivative.

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Quick View Somapacitan LA LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Somapacitan LA
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
  • Hormonal Disorders
  • Women’s Health
Key Developers
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.